Brittanie M Millang

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila et al. · The Lancet Oncology · 2020 · 357 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

Yelena Y. Janjigian, Joanne F. Chou, Marc Simmons et al. · Journal of Clinical Oncology · 2019 · 48 citations

Medicine, Oncology, Pharmacology +17

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

Ghassan K. Abou‐Alfa, Kristen Bibeau, Nikolaus Schultz et al. · Targeted Oncology · 2022 · 32 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

Imane El Dika, Marinela Capanu, Joanne F. Chou et al. · Cancer Medicine · 2020 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of <i>FGFR2 </i>alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.

Ghassan K. Abou‐Alfa, Kristen Bibeau, Nikolaus Schultz et al. · Journal of Clinical Oncology · 2021 · 15 citations

Medicine, Molecular Medicine, Oncology +13